智通财经APP获悉，康方生物(09926)早盘涨超5%，截至发稿，涨5.48%，报134.8港元，成交额5.55亿港元。
消息面上，4月30日，康方生物合作伙伴Summit Therapeutics披露，PD-1/VEGF双抗ivonescimab的三期HARMONi-3研究未按计划获得中期无进展生存期（PFS）结果。
中信证券（香港）表示，研究指出此次未达预期仅反映ivonescimab在预设严苛标准下未能在中期阶段显著超越Keytruda。分析强调，基于HARMONi-6的经验，预计在2026年下半年HARMONi-3中正常且较宽松的alpha分配下，该药有信心击败Keytruda。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.